Copd
Conditions
Brief summary
The purpose the study is to determine the agreement between the information obtained about lung mechanics (lung function) from the Rapid Expiratory Occlusion Monitor (REOM) handheld portable device with that obtained by conventional oscillometry as well as by pulmonary function testing (PFT), in patients with both 'mild' as well as 'very severe' forms of chronic obstructive pulmonary disease (COPD). This study also intends to study the user experience with this handheld portable device.
Detailed description
The primary objective of this cross-sectional study is to determine the concordance and agreement between the parameters obtained from the REOM, Reo1 and Reo2, and the conventional resistance parameters obtained by the tremoflo oscillometer device (R19 and R5, respectively) in adults with COPD confirmed by diagnostic pulmonary function testing (PFT). The secondary objectives are: 1. To investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD. 2. To collect descriptive information on the participant user experience with the REOM. 3. To determine concordance between the parameters obtained from the REOM and those obtained from the tremoflo oscillometry device with the 'standard' parameters obtained from each participant's standard Pulmonary Function Tests (PFT). Hypothesis: We hypothesize in the adult COPD patient population that the REOM parameter Reo1 and tremoflo device parameter R19 will correlate closely, and that the REOM parameter Reo2 and tremoflo device parameter R5 will correlate closely. We also hypothesize that the REOM, in particular, Reo2, will be able to distinguish between 'mild' and 'very severe' COPD, and that participants will report a positive user experience with the REOM.
Interventions
DEVICERapid Expiratory Occlusion Monitor (REOM)
Device for which Health Canada approval (ITA Authorization) has been obtained for use in the present study.
DIAGNOSTIC_TESTStandard oscillometry
tremoflo device-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada
DIAGNOSTIC_TESTStandard pulmonary function test
Standard-of-care respiratory test.
Sponsors
McGill University
Thorasys Thoracic Medical Systems Inc.
McGill University Health Centre/Research Institute of the McGill University Health Centre
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males and females aged ≥40 with COPD, former/current smokers with a ≥10 pack-year smoking history. * Diagnosed with COPD by FEV1/FVC \< 0.7 using standard PFT post-bronchodilator testing, with either 'mild' ('GOLD 1': FEV1 ≥ 80% of predicted value) COPD or 'very severe' ('GOLD 4': FEV1 \< 30% of predicted value) COPD. * Ability to provide informed consent.
Exclusion criteria
* No existing COPD diagnosis * History of co-morbid asthma * Current use of home oxygen * Any acute exacerbation of COPD (AECOPD) experienced within 4 weeks of participation in the study * Chronic respiratory infection * Any contraindication to respiratory testing * Inability to participate in reproducible measurements due to physical or cognitive barrier
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concordance (correlation) | Single-visit study: all tests performed at one single visit. | Correlation will be tested using the Spearman correlation coefficient (r) between REOM-obtained (Reo1 and Reo2) and tremoflo-obtained (R19 and R5) resistance measurements. |
| Agreement | Single-visit study: all tests performed at one single visit. | Agreement will be tested using the Bland-Altman test between REOM-obtained (Reo1 and Reo2) and tremoflo-obtained (R19 and R5) resistance measurements. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Discriminative capacity | Single-visit study: all tests performed at one single visit. | The t-test (between 2 independent means) will be used to determine the discriminative capacity of the REOM to distinguish between 'mild' and 'very severe' COPD. |
| Participant satisfaction and usability experience | Single-visit study: all tests performed at one single visit. | Each participant will complete a 'participant satisfaction questionnaire' as well as the validated System Usability Scale (SUS) for each test (REOM, standard oscillometry, pulmonary function test). Data will be presented descriptively. |
Countries
Canada
Outcome results
None listed